Literature DB >> 21512408

Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens.

Giuseppe Pelosi1, Giulio Rossi, Fabrizio Bianchi, Patrick Maisonneuve, Domenico Galetta, Angelica Sonzogni, Giulia Veronesi, Lorenzo Spaggiari, Mauro Papotti, Mattia Barbareschi, Paolo Graziano, Andrea Decensi, Alberto Cavazza, Giuseppe Viale.   

Abstract

INTRODUCTION: More detailed typing of non-small cell lung cancer on small biopsy specimens is increasingly required, albeit sometimes demanding with morphology alone. Little, however, is known about the likelihood of immunohistochemistry (IHC)-assessed small biopsies to effectively parallel profiling and, hence, eventual diagnoses of surgical specimens.
METHODS: Sixty-three preoperative biopsies and the corresponding surgical specimens from 30 consecutive squamous cell carcinomas, 22 adenocarcinomas, 2 adenosquamous carcinomas, eight sarcomatoid carcinomas, and one yolk sac tumor were jointly evaluated semiquantitatively for cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin immunoreactivity. Surgical specimens were the gold standard for morphology and IHC.
RESULTS: Hierarchic clustering analysis of both surgical specimens and biopsies showed a nonrandom and overlapping distribution of the relevant markers, which closely correlated with each other and the diverse tumor categories, as confirmed by mosaic plot analysis. There were no differences in area under the curve-receiver operating characteristic curves for each marker between any two samples, with the exception of p63 that paralleled more effectively squamous cell carcinoma on biopsies than surgical specimens. Fifty-nine of 63 (94%) lesions were correctly classified by IHC on biopsy compared with 53 of 63 (84%) by revised morphology, with the predictive positive value being 97% for squamous cell carcinoma, 88% for adenocarcinoma, and 100% for sarcomatoid and adenosquamous carcinoma. Yolk sac tumor and three of eight sarcomatoid carcinomas, however, failed any diagnostic recognition.
CONCLUSIONS: Diverse cell differentiation lineages of non-small cell lung cancer may be consistently detected by IHC in small biopsies, making the eventual typing of tumors effective in most cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512408     DOI: 10.1097/JTO.0b013e318211dd16

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  15 in total

1.  A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens.

Authors:  Diana Montezuma; Rosa Azevedo; Paula Lopes; Renata Vieira; Ana Luísa Cunha; Rui Henrique
Journal:  Virchows Arch       Date:  2013-10-15       Impact factor: 4.064

Review 2.  [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].

Authors:  G Kayser
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

3.  Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation.

Authors:  Wenfeng Fang; Jianwei Zhang; Wenhua Liang; Yan Huang; Yue Yan; Xuan Wu; Zhihuang Hu; Yuxiang Ma; Hongyun Zhao; Yuanyuan Zhao; Yunpeng Yang; Cong Xue; Jing Zhang; Li Zhang
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

4.  Volumetric optical frequency domain imaging of pulmonary pathology with precise correlation to histopathology.

Authors:  Lida P Hariri; Matthew B Applegate; Mari Mino-Kenudson; Eugene J Mark; Benjamin D Medoff; Andrew D Luster; Brett E Bouma; Guillermo J Tearney; Melissa J Suter
Journal:  Chest       Date:  2013-01       Impact factor: 9.410

5.  Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Authors:  Natasha Rekhtman; Paul K Paik; Maria E Arcila; Laura J Tafe; Geoffrey R Oxnard; Andre L Moreira; William D Travis; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

6.  Diagnostic patterns of non-small-cell lung cancer at Princess Margaret Cancer Centre.

Authors:  M Nadjafi; M R Sung; G D C Santos; L W Le; D M Hwang; M S Tsao; N B Leighl
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

7.  Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.

Authors:  Natasha Rekhtman; Laura J Tafe; Jamie E Chaft; Lu Wang; Maria E Arcila; Agnes Colanta; Andre L Moreira; Maureen F Zakowski; William D Travis; Camelia S Sima; Mark G Kris; Marc Ladanyi
Journal:  Mod Pathol       Date:  2012-11-30       Impact factor: 7.842

8.  Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples.

Authors:  Gian Kayser; Agnes Csanadi; Claudia Otto; Till Plönes; Nicola Bittermann; Justyna Rawluk; Bernward Passlick; Martin Werner
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

9.  Impact of histopathological diagnosis with ancillary immunohistochemical studies on lung cancer subtypes incidence and survival: a population-based study.

Authors:  Andrea Bordoni; Massimo Bongiovanni; Luca Mazzucchelli; Alessandra Spitale
Journal:  J Cancer Epidemiol       Date:  2011-12-29

10.  Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers.

Authors:  E Conde; B Angulo; E Izquierdo; L Paz-Ares; C Belda-Iniesta; M Hidalgo; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.